Synthesis, Biological Evaluation, and Theoretical Study of Indenoquinolinylphosphine Oxide Derivatives as Topoisomerase 1 Inhibitors and Antiproliferative Agents
ChemMedChem · 13.03.2026 · 21 (5)
DOI: 10.1002/cmdc.202500751 ↗Kurz gefasst
Fachartikel in der Zeitschrift ChemMedChem, online erschienen am 13.03.2026. Verfasst von Alba Rodriguez und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Organic Chemistry I, Faculty of Pharmacy, University of Basque Country (EHU), Vitoria-Gasteiz, Spain. Hauptthemen laut MEDLINE: Topoisomerase I Inhibitors, Antineoplastic Agents, DNA Topoisomerases, Type I, Quinolines. Die Arbeit nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministerio de Ciencia e Innovación, Hezkuntza, Hizkuntza Politika Eta KulturaSaila, Eusko Jaurlaritza, Ministry of Science and Innovation.
Abstract (Originalsprache)
The topoisomerase 1 (TOP1) enzymatic inhibition and antiproliferative activity of phosphorated indenoquinoline derivatives were investigated. First, the preparation of new hybrid quinoline and tetrahydroquinoline structures with a phosphine oxide group was performed by a two‐step Povarov type [4 + 2]‐cycloaddition reaction between the corresponding phosphorated aldimines with indene in the presence of BF 3 ·Et 2 O, affording corresponding 1,2,3,4‐tetrahydroindeno[2,1‐c]quinolinylphosphine oxides 9 , 7H‐indeno[2,1‐c]quinolinylphosphine oxides 10 and 7‐oxoindeno[2,1‐c]quinolinylphosphine oxides 11 with good yields. The synthesized derivatives were evaluated as TOP1 inhibitors, showing that some derivatives ( 9f , 9g , 9l , and 11m ) show better or similar activity to the reference compound (CPT) at 1 min. The synthesized derivatives were screened for their antiproliferative activity in different cancerous cell lines, and all of them present a higher selective cytotoxicity in the human lung adenocarcinoma cell line (A549), than in the others. In contrast, almost none of the synthesized phosphorated compounds exhibited antiproliferative activity toward nonmalignant lung fibroblasts MCR5. These results suggest that phosphine oxide‐substituted quinoline derivatives have important properties as TOP1 inhibitors and show an interesting cytotoxicity against six different cancerous cell lines.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Organic Chemistry I, Faculty of Pharmacy, University of Basque Country (EHU), Vitoria-Gasteiz, Spain.
- Department of Physical Chemistry, Faculty of Pharmacy, University of Basque Country (EHU), Vitoria-Gasteiz, Spain.
- Department of Molecular Biology and Genetics and Interdisciplinary Nanoscience Center (iNANO), Aarhus University, Aarhus, Denmark.
ORCID-Profile: Maria Fuertes, Concepcion Alonso
Förderung
- Ministerio de Ciencia e Innovación
- Hezkuntza, Hizkuntza Politika Eta KulturaSaila, Eusko Jaurlaritza
- Ministry of Science and Innovation
- Department of Education, Linguistic Policy and Culture, Basque Government
Zitieren
APA
Rodriguez, A., Formoso, E., Knudsen, B. R., Tesauro, C., Fuertes, M., & Alonso, C. (2026). Synthesis, Biological Evaluation, and Theoretical Study of Indenoquinolinylphosphine Oxide Derivatives as Topoisomerase 1 Inhibitors and Antiproliferative Agents. ChemMedChem, 21(5). https://doi.org/10.1002/cmdc.202500751
Vancouver
Rodriguez A, Formoso E, Knudsen BR, Tesauro C, Fuertes M, Alonso C. Synthesis, Biological Evaluation, and Theoretical Study of Indenoquinolinylphosphine Oxide Derivatives as Topoisomerase 1 Inhibitors and Antiproliferative Agents. ChemMedChem. 2026;21(5). doi:10.1002/cmdc.202500751
BibTeX
@article{Rodriguez2026,
author = {Rodriguez, Alba and Formoso, Elena and Knudsen, Birgitta R and Tesauro, Cinzia and Fuertes, Maria and Alonso, Concepcion},
title = {Synthesis, Biological Evaluation, and Theoretical Study of Indenoquinolinylphosphine Oxide Derivatives as Topoisomerase 1 Inhibitors and Antiproliferative Agents},
journal = {ChemMedChem},
year = {2026},
volume = {21},
number = {5},
doi = {10.1002/cmdc.202500751}
}
EUVIMED